The earnings call presented a strong performance in several key areas, including oncology and cardiovascular segments, and raised financial guidance for the year. However, challenges such as the significant impact of STELARA's loss of exclusivity and declines in specific segments like orthopedics were noted. Overall, the highlights slightly outweigh the lowlights.

Company Guidance -

Q3 2025

During the call, Johnson & Johnson provided guidance updates reflecting strong performance in the second quarter of fiscal year 2025. The company reported an operational sales growth of 4.6% and raised its full-year sales guidance by $2 billion, with earnings per share (EPS) guidance increased by $0.25 to a range of $10.80 to $10.90. Innovative Medicines sales grew by 3.8%, with oncology achieving a remarkable 22.3% operational sales growth. Medtech also delivered a robust 6.1% operational sales growth, driven by strengths in cardiovascular and surgery segments. Despite facing a significant headwind from the loss of exclusivity for STELARA, the company remains confident in its diversified portfolio, projecting sustained growth through strategic innovations and upcoming product launches in areas such as oncology, immunology, and neuroscience.

Operational Sales Growth

Johnson & Johnson reported an operational sales growth of 4.6% across its business in the second quarter, with the Innovative Medicines segment delivering 3.8% growth and MedTech achieving 6.1% growth.

Oncology Segment Performance

The oncology division reported operational sales growth of 22.3%, driven by multiple myeloma treatments and significant growth in prostate and lung cancer segments.

MedTech Cardiovascular Growth

The MedTech cardiovascular segment reported over 22% operational sales growth, driven by new product performance in Abiomed and Shockwave, and strength in electrophysiology.

Raised Financial Guidance

Johnson & Johnson raised its full-year sales guidance by $2 billion and EPS guidance by $0.25, from $10.60 to $10.85.

Johnson & Johnson (JNJ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JNJ Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 21, 2025	2025 (Q3)	2.75 / -	2.42	―	―	―
Jul 16, 2025	2025 (Q2)	2.68 / 2.77	2.82	-1.77% (-0.05)
Apr 15, 2025	2025 (Q1)	2.58 / 2.77	2.71	2.21% (+0.06)
Jan 22, 2025	2024 (Q4)	1.99 / 2.04	2.29	-10.92% (-0.25)
Oct 15, 2024	2024 (Q3)	2.21 / 2.42	2.66	-9.02% (-0.24)
Jul 17, 2024	2024 (Q2)	2.71 / 2.82	2.8	0.71% (+0.02)	―	―
Apr 16, 2024	2024 (Q1)	2.66 / 2.71	2.68	1.12% (+0.03)	―	―
Jan 23, 2024	2023 (Q4)	2.28 / 2.29	2.35	-2.55% (-0.06)	―	―
Oct 17, 2023	2023 (Q3)	2.52 / 2.66	2.55	4.31% (+0.11)	―	―
Jul 20, 2023	2023 (Q2)	2.62 / 2.80	2.59	8.11% (+0.21)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JNJ Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 16, 2025	$155.17	$164.78	+6.19%
Apr 15, 2025	$153.05	$152.31	-0.48%
Jan 22, 2025	$145.72	$142.89	-1.94%
Oct 15, 2024	$157.69	$160.13	+1.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.